Aldeyra
ALDX | NASDAQ
$0.68
+$0.04 (+5.62%)
At close: Nov 16, 2026, 3:59 PM ET
$0.67
-$0.01 (-1.53%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+5.62%
(1D)No price chart data available for 1D timeframe.
Rating
36.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #626/1021 (Top 61%)
Key Statistics
Market Data
Market Cap $40.99M
1D Range
0.65 0.69
52W Range
0.56 5.62
Valuation (TTM)
PE -2.12
PB 0.00
EV/EBITDA N/A
Valuation (NTM)
Forward PE 5.18
Forward PEG 0.06
Price Target $10.00
Cash Flow
FCF Yield -33726900.3%
SBC Adj. FCF Yield -38044131.8%
SBC Impact -12.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 35.8% |
22.1%
FCF 3Y | 5Y -150.0% |
-100.0%
Returns
ROA 0.0%
ROE 0.0%
ROIC 0.0%
Financial Health
Net Cash
$40.52T
Current Ratio 5.45
Interest Coverage -21.39
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species ...
Sector Healthcare
Industry Biotechnology
Employees 6
IPO Date May 2, 2014
Website www.aldeyra.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$10.00
Upside
+1370.59%
Buy (1)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ALDX